Mark Talamonti to Antibodies, Monoclonal
This is a "connection" page, showing publications Mark Talamonti has written about Antibodies, Monoclonal.
Connection Strength
1.218
-
Brodalumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2016 Dec; 12(12):1255-1271.
Score: 0.350
-
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Dermatology. 2011; 222(3):250-5.
Score: 0.239
-
The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol. 2010 Oct 01; 102(5):539-42.
Score: 0.230
-
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Score: 0.098
-
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. Mol Diagn Ther. 2016 06; 20(3):227-30.
Score: 0.085
-
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):476-82.
Score: 0.060
-
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. 2010; 221 Suppl 1:43-7.
Score: 0.057
-
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
Score: 0.052
-
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol. 2007 Apr; 156 Suppl 2:17-23.
Score: 0.045